Abstract
Atherosclerosis is a chronic inflammatory disorder of the arterial wall leading to coronary artery disease, stroke, and peripheral arterial disease. Along with the discovery of dipeptidyl peptidase 4 (DPP4) as a therapeutic target in type 2 diabetes, a role for DPP4 in atherosclerosis is emerging. However, until now the expression and role of other DPPs such as DPP8 and DPP9 in atherosclerosis is completely unknown. In the present study, we first investigated DPP expression in human atherosclerotic plaques. DPP4 could only be observed in endothelial cells of plaque neovessels in half of the specimens. In contrast, DPP8 and DPP9 were abundantly present in macrophage-rich regions of plaques. We then focused on DPP expression and function in macrophage differentiation, activation and apoptosis. DPP8/9 was responsible for most of the DPP activity in macrophages. During monocyte to macrophage differentiation, DPP9 was upregulated both in pro-inflammatory M1 (3.7 ± 0.3-fold increase) and anti-inflammatory M2 macrophages (3.7 ± 0.4-fold increase) whereas DPP8 expression remained unchanged. Inhibition of DPP8/9 activity with compound 1G244 reduced activation of M1 macrophages (IL-6 88 ± 16 vs. 146 ± 19 pg/ml; TNFα 3.8 ± 1.0 vs. 6.6 ± 1.9 ng/ml in treated vs. untreated cells), but not of M2 macrophages. Likewise, DPP9 silencing reduced TNFα and IL-6 secretion, pointing to a DPP9-mediated effect of the inhibitor. DPP8/9 inhibition also enhanced macrophage apoptosis (15 ± 4 vs. 7 ± 3 % in untreated cells). Because pro-inflammatory macrophages play a key role in atherogenesis, plaque rupture and subsequent infarction, DPP9 inhibition might provide interesting therapeutic prospects in reducing atherosclerosis and/or in the prevention of plaque rupture.
Similar content being viewed by others
Abbreviations
- AV:
-
Annexin V
- DPP:
-
Dipeptidyl peptidase
- ECs:
-
Endothelial cells
- GM-CSF:
-
Granulocyte macrophage-colony stimulating factor
- M-CSF:
-
Macrophage-colony stimulating factor
- MDMs:
-
Monocyte-derived macrophages
- Mo:
-
Monocytes
- Mφ:
-
Macrophages
- NPY:
-
Neuropeptide Y
- PI:
-
Propidium iodide
- PBMCs:
-
Peripheral blood mononuclear cells
- PMA:
-
Phorbol 12-myristate 13-acetate
- SMCs:
-
Smooth muscle cells
References
Abbott CA, Yu DM, Woollatt E, Sutherland GR, McCaughan GW, Gorrell MD (2000) Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. Eur J Biochem 267:6140–6150. doi:10.1046/j.1432-1327.2000.01617.x
Ajami K, Abbott CA, McCaughan GW, Gorrell MD (2004) Dipeptidyl peptidase 9 has two forms, a broad tissue distribution, cytoplasmic localization and DPIV-like peptidase activity. Biochim Biophys Acta 1679:18–28. doi:10.1016/j.bbaexp.2004.03.010
Ansorge S, Bank U, Heimburg A, Helmuth M, Koch G, Tadje J, Lendeckel U, Wolke C, Neubert K, Faust J, Fuchs P, Reinhold D, Thielitz A, Tager M (2009) Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and aminopeptidase N (APN) families in immune functions. Clin Chem Lab Med 47:253–261. doi:10.1515/CCLM.2009.063
Arakawa M, Mita T, Azuma K, Ebato C, Goto H, Nomiyama T, Fujitani Y, Hirose T, Kawamori R, Watada H (2010) Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 59:1030–1037. doi:10.2337/db09-1694
Bjelke JR, Christensen J, Nielsen PF, Branner S, Kanstrup AB, Wagtmann N, Rasmussen HB (2006) Dipeptidyl peptidases 8 and 9: specificity and molecular characterization compared with dipeptidyl peptidase IV. Biochem J 396:391–399. doi:10.1042/BJ20060079
Böyum A (1968) Isolation of mononuclear cells and granulocytes from human blood. Isolation of mononuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl 97:77–89
Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254. doi:10.1016/0003-2697(76)90527-3
Chrysant SG, Chrysant GS (2012) Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors. Am J Cardiol 109:1681–1685. doi:10.1016/j.amjcard.2012.01.398
Croons V, Martinet W, Herman AG, Timmermans JP, De Meyer GR (2007) Selective clearance of macrophages in atherosclerotic plaques by the protein synthesis inhibitor cycloheximide. J Pharmacol Exp Ther 320:986–993. doi:10.1124/jpet.106.113944
Daigneault M, Preston JA, Marriott HM, Whyte MK, Dockrell DH (2010) The identification of markers of macrophage differentiation in PMA-stimulated THP-1 cells and monocyte-derived macrophages. PLoS One 5:e8668. doi:10.1371/journal.pone.0008668
De Meester I, Scharpé S, Vanham G, Bosmans E, Heyligen H, Vanhoof G, Corte G (1993) Antibody binding profile of purified and cell-bound CD26. Designation of BT5/9 and TA5.9 to the CD26 cluster. Immunobiology 188:145–158. doi:10.1016/S0171-2985(11)80494-8
De Meyer I, Martinet W, Schrijvers DM, Timmermans JP, Bult H, De Meyer GR (2012) Toll-like receptor 7 stimulation by imiquimod induces macrophage autophagy and inflammation in atherosclerotic plaques. Basic Res Cardiol 107:269. doi:10.1007/s00395-012-0269-1
De Meyer I, Martinet W, Van Hove CE, Schrijvers DM, Hoymans VY, Van Vaeck L, Fransen P, Bult H, De Meyer GR (2011) Inhibition of inositol monophosphatase by lithium chloride induces selective macrophage apoptosis in atherosclerotic plaques. Br J Pharmacol 162:1410–1423. doi:10.1111/j.1476-5381.2010.01152.x
Deacon CF (2011) Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 13:7–18. doi:10.1111/j.1463-1326.2010.01306.x
Dubois V, Van Ginneken C, De Cock H, Lambeir AM, Van der Veken P, Augustyns K, Chen X, Scharpé S, De Meester I (2009) Enzyme activity and immunohistochemical localization of dipeptidyl peptidase 8 and 9 in male reproductive tissues. J Histochem Cytochem 57:531–541. doi:10.1369/jhc.2009.952739
ENCODE (2011) A user’s guide to the encyclopedia of DNA elements. PLoS Biol 9:e1001046. doi:10.1371/journal.pbio.1001046
Friedman AD (2007) Transcriptional control of granulocyte and monocyte development. Oncogene 26:6816–6828. doi:10.1038/sj.onc.1210764
Fukuhara M, Geary RL, Diz DI, Gallagher PE, Wilson JA, Glazier SS, Dean RH, Ferrario CM (2000) Angiotensin-converting enzyme expression in human carotid artery atherosclerosis. Hypertension 35:353–359. doi:10.1161/01.HYP.35.1.353
Fuster V, Badimon L, Badimon JJ, Chesebro JH (1992) The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 326:242–250. doi:10.1056/NEJM199201233260406
Geiss-Friedlander R, Parmentier N, Moller U, Urlaub H, Van den Eynde BJ, Melchior F (2009) The cytoplasmic peptidase DPP9 is rate-limiting for degradation of proline-containing peptides. J Biol Chem 284:27211–27219. doi:10.1074/jbc.M109.041871
Kohlstedt K, Trouvain C, Namgaladze D, Fleming I (2011) Adipocyte-derived lipids increase angiotensin-converting enzyme (ACE) expression and modulate macrophage phenotype. Basic Res Cardiol 106:205–215. doi:10.1007/s00395-010-0137-9
Krijnen PA, Hahn NE, Kholova I, Baylan U, Sipkens JA, van Alphen FP, Vonk AB, Simsek S, Meischl C, Schalkwijk CG, van Buul JD, van Hinsbergh VW, Niessen HW (2012) Loss of DPP4 activity is related to a prothrombogenic status of endothelial cells: implications for the coronary microvasculature of myocardial infarction patients. Basic Res Cardiol 107:233. doi:10.1007/s00395-011-0233-5
Lambeir AM, Durinx C, Scharpé S, De Meester I (2003) Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 40:209–294. doi:10.1080/713609354
Lambeir AM, Scharpé S, De Meester I (2008) DPP4 inhibitors for diabetes—what next? Biochem Pharmacol 76:1637–1643. doi:10.1016/j.bcp.2008.07.029
Lankas GR, Leiting B, Roy RS, Eiermann GJ, Beconi MG, Biftu T, Chan CC, Edmondson S, Feeney WP, He H, Ippolito DE, Kim D, Lyons KA, Ok HO, Patel RA, Petrov AN, Pryor KA, Qian X, Reigle L, Woods A, Wu JK, Zaller D, Zhang X, Zhu L, Weber AE, Thornberry NA (2005) Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 54:2988–2994. doi:10.2337/diabetes.54.10.2988
Lee HJ, Chen YS, Chou CY, Chien CH, Lin CH, Chang GG, Chen X (2006) Investigation of the dimer interface and substrate specificity of prolyl dipeptidase DPP8. J Biol Chem 281:38653–38662. doi:10.1074/jbc.M603895200
Li L, Najafi AH, Kitlinska JB, Neville R, Laredo J, Epstein SE, Burnett MS, Zukowska Z (2011) Of mice and men: neuropeptide y and its receptors are associated with atherosclerotic lesion burden and vulnerability. J Cardiovasc Transl Res 4:351–362. doi:10.1007/s12265-011-9271-5
Lojda Z (1979) Studies on dipeptidyl(amino)peptidase IV (glycyl-proline naphthylamidase). II. Blood vessels. Histochemistry 59:153–166. doi:10.1007/BF00495663
Lu C, Tilan JU, Everhart L, Czarnecka M, Soldin SJ, Mendu DR, Jeha D, Hanafy J, Lee CK, Sun J, Izycka-Swieszewska E, Toretsky JA, Kitlinska J (2011) Dipeptidyl peptidases as survival factors in Ewing sarcoma family of tumors: implications for tumor biology and therapy. J Biol Chem 286:27494–27505. doi:10.1074/jbc.M111.224089
Maes MB, Dubois V, Brandt I, Lambeir AM, Van der Veken P, Augustyns K, Cheng JD, Chen X, Scharpé S, De Meester I (2007) Dipeptidyl peptidase 8/9-like activity in human leukocytes. J Leukoc Biol 81:1252–1257. doi:10.1189/jlb.0906546
Martinet W, Verheye S, De Meyer GR (2007) Selective depletion of macrophages in atherosclerotic plaques via macrophage-specific initiation of cell death. Trends Cardiovasc Med 17:69–75. doi:10.1016/j.tcm.2006.12.004
Matheeussen V, Baerts L, De Meyer G, De Keulenaer G, Van der Veken P, Augustyns K, Dubois V, Scharpe S, De Meester I (2011) Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries. Biol Chem 392:189–198. doi:10.1515/BC.2011.002
Matheeussen V, Jungraithmayr W, De Meester I (2012) Dipeptidyl peptidase IV as a therapeutic target in ischemia-reperfusion injury. Pharmacol Ther 136:267–282. doi:10.1016/j.pharmthera.2012.07.012
Matheeussen V, Lambeir AM, Jungraithmayr W, Gomez N, Mc Entee K, Van der Veken P, Scharpe S, De Meester I (2012) Method comparison of dipeptidyl peptidase IV activity assays and their application in biological samples containing reversible inhibitors. Clin Chim Acta 413:456–462. doi:10.1016/j.cca.2011.10.031
Matsubara J, Sugiyama S, Sugamura K, Nakamura T, Fujiwara Y, Akiyama E, Kurokawa H, Nozaki T, Ohba K, Konishi M, Maeda H, Izumiya Y, Kaikita K, Sumida H, Jinnouchi H, Matsui K, Kim-Mitsuyama S, Takeya M, Ogawa H (2012) A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein e-deficient mice. J Am Coll Cardiol 59:265–276. doi:10.1016/j.jacc.2011.07.053
Monami M, Lamanna C, Desideri CM, Mannucci E (2012) DPP-4 inhibitors and lipids: systematic review and meta-analysis. Adv Ther 29:14–25. doi:10.1007/s12325-011-0088-z
Nagashima M, Watanabe T, Terasaki M, Tomoyasu M, Nohtomi K, Kim-Kaneyama J, Miyazaki A, Hirano T (2011) Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice. Diabetologia 54:2649–2659. doi:10.1007/s00125-011-2241-2
Olsen C, Wagtmann N (2002) Identification and characterization of human DPP9, a novel homologue of dipeptidyl peptidase IV. Gene 299:185–193. doi:10.1016/S0378-1119(02)01059-4
Pennington KN, Taylor JA, Bren GD, Paya CV (2001) IkappaB kinase-dependent chronic activation of NF-kappaB is necessary for p21(WAF1/Cip1) inhibition of differentiation-induced apoptosis of monocytes. Mol Cell Biol 21:1930–1941. doi:10.1128/MCB.21.6.1930-1941.2001
Pilla E, Moller U, Sauer G, Mattiroli F, Melchior F, Geiss-Friedlander R (2012) A novel SUMO1-specific interacting motif in Dipeptidyl peptidase 9 (DPP9) that is important for enzymatic regulation. J Biol Chem 287:44320–44329. doi:10.1074/jbc.M112.397224
Reinhold D, Goihl A, Wrenger S, Reinhold A, Kuhlmann UC, Faust J, Neubert K, Thielitz A, Brocke S, Tager M, Ansorge S, Bank U (2009) Role of dipeptidyl peptidase IV (DP IV)-like enzymes in T lymphocyte activation: investigations in DP IV/CD26-knockout mice. Clin Chem Lab Med 47:268–274. doi:10.1515/CCLM.2009.062
Ross R (1999) Atherosclerosis—an inflammatory disease. N Engl J Med 340:115–126. doi:10.1056/NEJM199901143400207
Schade J, Stephan M, Schmiedl A, Wagner L, Niestroj AJ, Demuth HU, Frerker N, Klemann C, Raber KA, Pabst R, von Horsten S (2008) Regulation of expression and function of dipeptidyl peptidase 4 (DP4), DP8/9, and DP10 in allergic responses of the lung in rats. J Histochem Cytochem 56:147–155. doi:10.1369/jhc.7A7319.2007
Shah Z, Kampfrath T, Deiuliis JA, Zhong J, Pineda C, Ying Z, Xu X, Lu B, Moffatt-Bruce S, Durairaj R, Sun Q, Mihai G, Maiseyeu A, Rajagopalan S (2011) Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation 124:2338–2349. doi:10.1161/CIRCULATIONAHA.111.041418
Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, Howard BV, Kirkman MS, Kosiborod M, Reaven P, Sherwin RS (2009) Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol 53:298–304. doi:10.1016/j.jacc.2008.10.008
Sordet O, Bettaieb A, Bruey JM, Eymin B, Droin N, Ivarsson M, Garrido C, Solary E (1999) Selective inhibition of apoptosis by TPA-induced differentiation of U937 leukemic cells. Cell Death Differ 6:351–361. doi:10.1038/sj.cdd.4400499
Spagnuolo PA, Hurren R, Gronda M, Maclean N, Datti A, Basheer A, Lin FH, Wang X, Wrana J, Schimmer AD (2013) Inhibition of intracellular dipeptidyl peptidases 8 and 9 enhances parthenolide’s anti-leukemic activity. Leukemia. doi:10.1038/leu.2013.9
Ta NN, Schuyler CA, Li Y, Lopes-Virella MF, Huang Y (2011) DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 58:157–166. doi:10.1097/FJC.0b013e31821e5626
Tedgui A, Mallat Z (2006) Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 86:515–581. doi:10.1152/physrev.00024.2005
Terasaki M, Nagashima M, Watanabe T, Nohtomi K, Mori Y, Miyazaki A, Hirano T (2012) Effects of PKF275-055, a dipeptidyl peptidase-4 inhibitor, on the development of atherosclerotic lesions in apolipoprotein E-null mice. Metab 61:974–977. doi:10.1016/j.metabol.2011.11.011
Ussher JR, Drucker DJ (2012) Cardiovascular biology of the incretin system. Endocr Rev 33:187–215. doi:10.1210/er.2011-1052
Valledor AF, Borras FE, Cullell-Young M, Celada A (1998) Transcription factors that regulate monocyte/macrophage differentiation. J Leukoc Biol 63:405–417
Van Goethem S, Matheeussen V, Joossens J, Lambeir AM, Chen X, De Meester I, Haemers A, Augustyns K, Van der Veken P (2011) Structure-activity relationship studies on isoindoline inhibitors of dipeptidyl peptidases 8 and 9 (DPP8, DPP9): is DPP8-selectivity an attainable goal? J Med Chem 54:5737–5746. doi:10.1021/jm200383j
Verreck FA, de Boer T, Langenberg DM, van der Zanden L, Ottenhoff TH (2006) Phenotypic and functional profiling of human proinflammatory type-1 and anti-inflammatory type-2 macrophages in response to microbial antigens and IFN-gamma- and CD40L-mediated costimulation. J Leukoc Biol 79:285–293. doi:10.1189/jlb.0105015
Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM (2000) Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 20:1262–1275. doi:10.1161/01.ATV.20.5.1262
Wu JJ, Tang HK, Yeh TK, Chen CM, Shy HS, Chu YR, Chien CH, Tsai TY, Huang YC, Huang YL, Huang CH, Tseng HY, Jiaang WT, Chao YS, Chen X (2009) Biochemistry, pharmacokinetics, and toxicology of a potent and selective DPP8/9 inhibitor. Biochem Pharmacol 78:203–210. doi:10.1016/j.bcp.2009.03.032
Yan D, Davis FJ, Sharrocks AD, Im HJ (2010) Emerging roles of SUMO modification in arthritis. Gene 466:1–15. doi:10.1016/j.gene.2010.07.003
Ye Y, Perez-Polo JR, Aguilar D, Birnbaum Y (2011) The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury. Basic Res Cardiol 106:925–952. doi:10.1007/s00395-011-0216-6
Yu DM, Ajami K, Gall MG, Park J, Lee CS, Evans KA, McLaughlin EA, Pitman MR, Abbott CA, McCaughan GW, Gorrell MD (2009) The in vivo expression of dipeptidyl peptidases 8 and 9. J Histochem Cytochem 57:1025–1040. doi:10.1369/jhc.2009.953760
Yu DM, Yao TW, Chowdhury S, Nadvi NA, Osborne B, Church WB, McCaughan GW, Gorrell MD (2010) The dipeptidyl peptidase IV family in cancer and cell biology. FEBS J 277:1126–1144. doi:10.1111/j.1742-4658.2009.07526.x
Acknowledgments
This work was supported by the Fund for Scientific Research Flanders (Belgium, FWO-Vlaanderen, Grant no. G016209) and by GOA BOF and TOP BOF (Research Council, Special Fund for Research, University of Antwerp). Veerle Matheeussen and Yannick Waumans are research assistants of FWO-Vlaanderen. We are grateful to Mrs. Rita Van Den Bossche and Mrs. Yani Sim for their excellent technical assistance.
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Matheeussen, V., Waumans, Y., Martinet, W. et al. Dipeptidyl peptidases in atherosclerosis: expression and role in macrophage differentiation, activation and apoptosis. Basic Res Cardiol 108, 350 (2013). https://doi.org/10.1007/s00395-013-0350-4
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00395-013-0350-4